0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Mental Disorders Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-12T6869
Home | Market Reports | Health| Mental Health
Global Mental Disorders Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Mental Disorders Drugs Market Research Report 2025

Code: QYRE-Auto-12T6869
Report
September 2025
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Mental Disorders Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Mental Disorders Drugs Market

Mental Disorders Drugs Market

The global market for Mental Disorders Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Mental Disorders Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mental Disorders Drugs.
The Mental Disorders Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Mental Disorders Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Mental Disorders Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Mental Disorders Drugs Market Report

Report Metric Details
Report Name Mental Disorders Drugs Market
CAGR 5%
Segment by Type
  • Drugs for Schizophrenia
  • Antidepressants
  • Antipsychotics
  • Anxiolytics
  • Drugs for the Treatment of Substance and Alcohol Addiction
  • Drugs for Childhood and Adolescent Mental Illness
  • Drugs to Treat Cognitive Disorders
  • Sleep Disorders
  • Others
Segment by Application
  • Children
  • Adolescents
  • Adults
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Mental Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Mental Disorders Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Mental Disorders Drugs Market report?

Ans: The main players in the Mental Disorders Drugs Market are Johnson & Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Abbott Laboratories

What are the Application segmentation covered in the Mental Disorders Drugs Market report?

Ans: The Applications covered in the Mental Disorders Drugs Market report are Children, Adolescents, Adults

What are the Type segmentation covered in the Mental Disorders Drugs Market report?

Ans: The Types covered in the Mental Disorders Drugs Market report are Drugs for Schizophrenia, Antidepressants, Antipsychotics, Anxiolytics, Drugs for the Treatment of Substance and Alcohol Addiction, Drugs for Childhood and Adolescent Mental Illness, Drugs to Treat Cognitive Disorders, Sleep Disorders, Others

1 Mental Disorders Drugs Market Overview
1.1 Product Definition
1.2 Mental Disorders Drugs by Type
1.2.1 Global Mental Disorders Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Drugs for Schizophrenia
1.2.3 Antidepressants
1.2.4 Antipsychotics
1.2.5 Anxiolytics
1.2.6 Drugs for the Treatment of Substance and Alcohol Addiction
1.2.7 Drugs for Childhood and Adolescent Mental Illness
1.2.8 Drugs to Treat Cognitive Disorders
1.2.9 Sleep Disorders
1.2.10 Others
1.3 Mental Disorders Drugs by Application
1.3.1 Global Mental Disorders Drugs Market Value by Application (2024 VS 2031)
1.3.2 Children
1.3.3 Adolescents
1.3.4 Adults
1.4 Global Mental Disorders Drugs Market Size Estimates and Forecasts
1.4.1 Global Mental Disorders Drugs Revenue 2020-2031
1.4.2 Global Mental Disorders Drugs Sales 2020-2031
1.4.3 Global Mental Disorders Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Mental Disorders Drugs Market Competition by Manufacturers
2.1 Global Mental Disorders Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Mental Disorders Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Mental Disorders Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Mental Disorders Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Mental Disorders Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Mental Disorders Drugs, Product Type & Application
2.7 Global Key Manufacturers of Mental Disorders Drugs, Date of Enter into This Industry
2.8 Global Mental Disorders Drugs Market Competitive Situation and Trends
2.8.1 Global Mental Disorders Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Mental Disorders Drugs Players Market Share by Revenue
2.8.3 Global Mental Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Mental Disorders Drugs Market Scenario by Region
3.1 Global Mental Disorders Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Mental Disorders Drugs Sales by Region: 2020-2031
3.2.1 Global Mental Disorders Drugs Sales by Region: 2020-2025
3.2.2 Global Mental Disorders Drugs Sales by Region: 2026-2031
3.3 Global Mental Disorders Drugs Revenue by Region: 2020-2031
3.3.1 Global Mental Disorders Drugs Revenue by Region: 2020-2025
3.3.2 Global Mental Disorders Drugs Revenue by Region: 2026-2031
3.4 North America Mental Disorders Drugs Market Facts & Figures by Country
3.4.1 North America Mental Disorders Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Mental Disorders Drugs Sales by Country (2020-2031)
3.4.3 North America Mental Disorders Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Mental Disorders Drugs Market Facts & Figures by Country
3.5.1 Europe Mental Disorders Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Mental Disorders Drugs Sales by Country (2020-2031)
3.5.3 Europe Mental Disorders Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Mental Disorders Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Mental Disorders Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Mental Disorders Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Mental Disorders Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Mental Disorders Drugs Market Facts & Figures by Country
3.7.1 Latin America Mental Disorders Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Mental Disorders Drugs Sales by Country (2020-2031)
3.7.3 Latin America Mental Disorders Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Mental Disorders Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Mental Disorders Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Mental Disorders Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Mental Disorders Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Mental Disorders Drugs Sales by Type (2020-2031)
4.1.1 Global Mental Disorders Drugs Sales by Type (2020-2025)
4.1.2 Global Mental Disorders Drugs Sales by Type (2026-2031)
4.1.3 Global Mental Disorders Drugs Sales Market Share by Type (2020-2031)
4.2 Global Mental Disorders Drugs Revenue by Type (2020-2031)
4.2.1 Global Mental Disorders Drugs Revenue by Type (2020-2025)
4.2.2 Global Mental Disorders Drugs Revenue by Type (2026-2031)
4.2.3 Global Mental Disorders Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Mental Disorders Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Mental Disorders Drugs Sales by Application (2020-2031)
5.1.1 Global Mental Disorders Drugs Sales by Application (2020-2025)
5.1.2 Global Mental Disorders Drugs Sales by Application (2026-2031)
5.1.3 Global Mental Disorders Drugs Sales Market Share by Application (2020-2031)
5.2 Global Mental Disorders Drugs Revenue by Application (2020-2031)
5.2.1 Global Mental Disorders Drugs Revenue by Application (2020-2025)
5.2.2 Global Mental Disorders Drugs Revenue by Application (2026-2031)
5.2.3 Global Mental Disorders Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Mental Disorders Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Company Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Johnson & Johnson Mental Disorders Drugs Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer Mental Disorders Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Company Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Eli Lilly Mental Disorders Drugs Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Company Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Mental Disorders Drugs Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 AstraZeneca Mental Disorders Drugs Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb Mental Disorders Drugs Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Abbott Laboratories
6.7.1 Abbott Laboratories Company Information
6.7.2 Abbott Laboratories Description and Business Overview
6.7.3 Abbott Laboratories Mental Disorders Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Abbott Laboratories Mental Disorders Drugs Product Portfolio
6.7.5 Abbott Laboratories Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Mental Disorders Drugs Industry Chain Analysis
7.2 Mental Disorders Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Mental Disorders Drugs Production Mode & Process Analysis
7.4 Mental Disorders Drugs Sales and Marketing
7.4.1 Mental Disorders Drugs Sales Channels
7.4.2 Mental Disorders Drugs Distributors
7.5 Mental Disorders Drugs Customer Analysis
8 Mental Disorders Drugs Market Dynamics
8.1 Mental Disorders Drugs Industry Trends
8.2 Mental Disorders Drugs Market Drivers
8.3 Mental Disorders Drugs Market Challenges
8.4 Mental Disorders Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Mental Disorders Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Mental Disorders Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Mental Disorders Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Mental Disorders Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Mental Disorders Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Mental Disorders Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Mental Disorders Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Mental Disorders Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Mental Disorders Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Mental Disorders Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Mental Disorders Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Mental Disorders Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Mental Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mental Disorders Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Mental Disorders Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Mental Disorders Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Mental Disorders Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Mental Disorders Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Mental Disorders Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Mental Disorders Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Mental Disorders Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Mental Disorders Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Mental Disorders Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Mental Disorders Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Mental Disorders Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Mental Disorders Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Mental Disorders Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Mental Disorders Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Mental Disorders Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Mental Disorders Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Mental Disorders Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Mental Disorders Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Mental Disorders Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Mental Disorders Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Mental Disorders Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Mental Disorders Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Mental Disorders Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Mental Disorders Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Mental Disorders Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Mental Disorders Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Mental Disorders Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Mental Disorders Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Mental Disorders Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Mental Disorders Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Mental Disorders Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Mental Disorders Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Mental Disorders Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Mental Disorders Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Mental Disorders Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Mental Disorders Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Mental Disorders Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Mental Disorders Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Mental Disorders Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Mental Disorders Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Mental Disorders Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Mental Disorders Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Mental Disorders Drugs Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Mental Disorders Drugs Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Mental Disorders Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Mental Disorders Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Mental Disorders Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Mental Disorders Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Mental Disorders Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Mental Disorders Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Mental Disorders Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Mental Disorders Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Mental Disorders Drugs Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Mental Disorders Drugs Price (USD/Pcs) by Application (2026-2031)
 Table 70. Johnson & Johnson Company Information
 Table 71. Johnson & Johnson Description and Business Overview
 Table 72. Johnson & Johnson Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Johnson & Johnson Mental Disorders Drugs Product
 Table 74. Johnson & Johnson Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Pfizer Mental Disorders Drugs Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Eli Lilly Company Information
 Table 81. Eli Lilly Description and Business Overview
 Table 82. Eli Lilly Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Eli Lilly Mental Disorders Drugs Product
 Table 84. Eli Lilly Recent Developments/Updates
 Table 85. GlaxoSmithKline Company Information
 Table 86. GlaxoSmithKline Description and Business Overview
 Table 87. GlaxoSmithKline Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. GlaxoSmithKline Mental Disorders Drugs Product
 Table 89. GlaxoSmithKline Recent Developments/Updates
 Table 90. AstraZeneca Company Information
 Table 91. AstraZeneca Description and Business Overview
 Table 92. AstraZeneca Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. AstraZeneca Mental Disorders Drugs Product
 Table 94. AstraZeneca Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Information
 Table 96. Bristol-Myers Squibb Description and Business Overview
 Table 97. Bristol-Myers Squibb Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Mental Disorders Drugs Product
 Table 99. Bristol-Myers Squibb Recent Developments/Updates
 Table 100. Abbott Laboratories Company Information
 Table 101. Abbott Laboratories Description and Business Overview
 Table 102. Abbott Laboratories Mental Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. Abbott Laboratories Mental Disorders Drugs Product
 Table 104. Abbott Laboratories Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Mental Disorders Drugs Distributors List
 Table 108. Mental Disorders Drugs Customers List
 Table 109. Mental Disorders Drugs Market Trends
 Table 110. Mental Disorders Drugs Market Drivers
 Table 111. Mental Disorders Drugs Market Challenges
 Table 112. Mental Disorders Drugs Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Mental Disorders Drugs
 Figure 2. Global Mental Disorders Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Mental Disorders Drugs Market Share by Type: 2024 & 2031
 Figure 4. Drugs for Schizophrenia Product Picture
 Figure 5. Antidepressants Product Picture
 Figure 6. Antipsychotics Product Picture
 Figure 7. Anxiolytics Product Picture
 Figure 8. Drugs for the Treatment of Substance and Alcohol Addiction Product Picture
 Figure 9. Drugs for Childhood and Adolescent Mental Illness Product Picture
 Figure 10. Drugs to Treat Cognitive Disorders Product Picture
 Figure 11. Sleep Disorders Product Picture
 Figure 12. Others Product Picture
 Figure 13. Global Mental Disorders Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 14. Global Mental Disorders Drugs Market Share by Application: 2024 & 2031
 Figure 15. Children
 Figure 16. Adolescents
 Figure 17. Adults
 Figure 18. Global Mental Disorders Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 19. Global Mental Disorders Drugs Market Size (2020-2031) & (US$ Million)
 Figure 20. Global Mental Disorders Drugs Sales (2020-2031) & (K Units)
 Figure 21. Global Mental Disorders Drugs Average Price (USD/Pcs) & (2020-2031)
 Figure 22. Mental Disorders Drugs Report Years Considered
 Figure 23. Mental Disorders Drugs Sales Share by Manufacturers in 2024
 Figure 24. Global Mental Disorders Drugs Revenue Share by Manufacturers in 2024
 Figure 25. Global 5 and 10 Largest Mental Disorders Drugs Players: Market Share by Revenue in Mental Disorders Drugs in 2024
 Figure 26. Mental Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 27. Global Mental Disorders Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 28. North America Mental Disorders Drugs Sales Market Share by Country (2020-2031)
 Figure 29. North America Mental Disorders Drugs Revenue Market Share by Country (2020-2031)
 Figure 30. U.S. Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Canada Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Europe Mental Disorders Drugs Sales Market Share by Country (2020-2031)
 Figure 33. Europe Mental Disorders Drugs Revenue Market Share by Country (2020-2031)
 Figure 34. Germany Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. France Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. U.K. Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Italy Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Russia Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Asia Pacific Mental Disorders Drugs Sales Market Share by Region (2020-2031)
 Figure 40. Asia Pacific Mental Disorders Drugs Revenue Market Share by Region (2020-2031)
 Figure 41. China Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Japan Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. South Korea Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. India Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Australia Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Taiwan Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Indonesia Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Thailand Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Malaysia Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Philippines Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Latin America Mental Disorders Drugs Sales Market Share by Country (2020-2031)
 Figure 52. Latin America Mental Disorders Drugs Revenue Market Share by Country (2020-2031)
 Figure 53. Mexico Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Brazil Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Argentina Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Middle East and Africa Mental Disorders Drugs Sales Market Share by Country (2020-2031)
 Figure 57. Middle East and Africa Mental Disorders Drugs Revenue Market Share by Country (2020-2031)
 Figure 58. Turkey Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Saudi Arabia Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 60. U.A.E Mental Disorders Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 61. Global Sales Market Share of Mental Disorders Drugs by Type (2020-2031)
 Figure 62. Global Revenue Market Share of Mental Disorders Drugs by Type (2020-2031)
 Figure 63. Global Mental Disorders Drugs Price (USD/Pcs) by Type (2020-2031)
 Figure 64. Global Sales Market Share of Mental Disorders Drugs by Application (2020-2031)
 Figure 65. Global Revenue Market Share of Mental Disorders Drugs by Application (2020-2031)
 Figure 66. Global Mental Disorders Drugs Price (USD/Pcs) by Application (2020-2031)
 Figure 67. Mental Disorders Drugs Value Chain
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Accenture

SIMILAR REPORTS

RELATED REPORTS

Global Mental Disorders Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12T6869
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Haloperidol Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15F3292
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Serotonin Suppliments Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26K6727
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Major Tranquilizers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33X6826
Tue Sep 09 00:00:00 UTC 2025

Add to Cart